Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth

CompletedOBSERVATIONAL
Enrollment

126

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

March 31, 2017

Conditions
Preterm LabourPreterm Birth
Interventions
DEVICE

novel kit for the detection of PAMG-1

The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.

Trial Locations (1)

3010

Prof. Dr. Daniel Surbek, Bern

Sponsors
All Listed Sponsors
collaborator

AmniSure International LLC

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT02092688 - Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth | Biotech Hunter | Biotech Hunter